Company intelligence / Profile preview

MiddleBrook Pharmaceuticals

Westlake, Texas, United States

Ownership: Private
Employees: ~299
Development stage: Other

Overview

MiddleBrook Pharmaceuticals developed pulsatile delivery antibiotic products, with the commercial launch of FDA-approved MOXATAG (once-daily amoxicillin) and marketed KEFLEX (immediate-release cephalexin). The company’s approach aimed to improve dosing convenience and compliance but is no longer actively developing products.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

amoxicillin PULSYS

Unknown

Partnerships

Equity Group Investments (investor/strategic partner)[4][6]

Beyond the preview

Go deeper on MiddleBrook Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiddleBrook Pharmaceuticals.

Explore the full profile